Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): A children's oncology group report

American Journal of Transplantation

Volumn 12, Issue 11, 2012, Pages 3069-3075

  Gross, T G ^a   Orjuela, M A ^b   Perkins, S L ^c   Park, J R ^d   Lynch, J C ^e   Cairo, M S ^f   Smith, L M ^e   Hayashi, R J ^g  

^a OHIO STATE UNIVERSITY   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^f NEW YORK MEDICAL COLLEGE   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; EBV; PTLD; rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB;

ADOLESCENT; ARTICLE; BASAL CELL CARCINOMA; CANCER REGRESSION; CANCER STAGING; CHILD; CHILDHOOD DISEASE; DRUG EFFICACY; EPSTEIN BARR VIRUS INFECTION; EVENT FREE SURVIVAL; FEMALE; FEVER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INFECTION; LEIOMYOSARCOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ORGAN TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SOLID ORGAN TRANSPLANTION; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MAXIMUM TOLERATED DOSE; ORGAN TRANSPLANTATION; PREDNISONE; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84868210644     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04206.x     Document Type: Article

References (27)

1. Dharnidharka VR, Tejani AH, Ho Pl, Harmon WE,. Post-transplant lymphoproliferative disorder in the United States: Young Caucasian males at highest risk. Am J Transplant 2002; 2: 993-998.
2. Newell KA, Alonso EM, Whitington PF, et al,. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996; 62: 370-375.
3. Allen UD, Farkas G, Hébert D, et al,. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: A case-control study. Pediatr Transplant 2005; 9: 450-455.
4. Maecker B, Jack T, Zimmermann M, et al,. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol. 2007; 25: 4902-4908.
5. Webber SA, Naftel DC, Fricker FJ, et al,. Lymphoproliferative disorders after paediatric heart transplantation: Multi-institutional study. Lancet 2006; 367: 233-239.
6. Hayashi RJ, Kraus MD, Patel AL, et al,. Posttransplant lymphoproliferative disease in children: Correlation of histology to clinical behavior. J Pediatr Hematol Oncol 2001; 23: 14-18.
7. Reshef R, Vardhanabhuti S, Luskin MR, et al,. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant 2011; 11: 336-347.
8. Gross TG, Bucuvalas JC, Park JR, et al,. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005; 23: 6481-6488.
9. Oertel SH, Verschuuren E, Reinke P, et al,. Effect of anti-CD20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5: 2901-2906.
10. Choquet S, Leblond V, Herbrecht R, et al,. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053-3057.
11. Elstrom RL, Andreadis C, Aqui NA, et al,. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569-576.
12. Trappe RU, Choquet S, Reinke P, et al,. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after upfront chemotherapy: The role of single-agent rituximab. Transplantation. 2007; 84: 1708-1712.
13. Choquet S, Trappe R, Leblond V, Jäger U, Davi F, Oertel S,. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007; 92: 273-274.
14. Trappe R, Oertel S, Leblond V, et al,. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196-206.
15. Swerdlow SH, Webber SA, Chadburn A,. Post-transplant lymphoproliferative disorders. In:, Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer, 2008: 343-349.
16. Murphy SB, Fairclough DL, Hutchison RE, Berard CW,. Non-Hodgkin's lymphomas of childhood: An analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 1909; 7: 186-193.
17. Gupta S, Fricker FJ, González-Peralta RP, Slayton WB, Schuler PM, Dharnidharka VR,. Post-transplant lymphoproliferative disorder in children: Recent outcomes and response to dual rituximab/low-dose chemotherapy combination. Pediatr Transplant 2010; 14: 896-902.
18. Orjuela M, Gross TG, Cheung YK, Alobeid B, Morris E, Cairo MS,. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 2003; 9 (10 Pt 2): 3945S-3952S.
19. Coiffer B, Haioun C, Ketterer N, et al,. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multi-center phase II study. Blood 1998; 92: 1927-1932.
20. Cairo MS, Lynch JC, Harrison L, et al,. Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (group B) and BM+/CNS+ (group C) mature B-NHL: A Children's Oncology Group report. J Clin Oncol 2010; 28: 687s.
21. hi T lymphocytes in mice: Implications for strategies of chemoimmunotherapy of cancer. Blood 2000; 95: 2024-2030.
22. Picarsic J, Jaffe R, Mazariegos G, et al,. Post-transplant Burkitt lymphoma is a more aggressive and distinct form of post-transplant lymphoproliferative disorder. Cancer 2011; 117: 4540-4550.
23. Windebank K, Walwyn T, Kirk R, et al,. Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14)Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab. Pediatr Blood Cancer 2009; 53: 392-3966.
24. Buell JF, Gross TG, Hanaway MJ, et al,. Posttransplant lymphoproliferative disorder: Significance of central nervous system involvement. Transplant Proc 2005; 37: 954-955.
25. Orjuela MA, Alobeid B, Liu X, et al,. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation. Br J Haematol 2011; 152: 733-742.
26. Ghobrial IM, Habermann TM, Ristow KM, et al,. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005; 46: 191-196.
27. Dharnidharka VR, Martz KL, Stablein DM, Benfield MR,. Improved survival with recent post-transplant lymphoproliferative disorder (PTLD) in children with kidney transplants. Am J Transplant 2011; 11: 751-758.